Migraine Trial, Recruiting NCT06690060 Sponsor: Beth Israel Deaconess Medical Center Condition: Migraine
Back to Migraine

Migraine Trial, Recruiting

NCT06690060
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have previously been diagnosed with migraine headaches by a doctor
  • Your migraines have a moderate or greater impact on your daily life, based on a standard headache questionnaire (confirm with trial site)
  • You experience migraine headaches on at least 5 days per month
  • You are willing to take part in a mind-body wellness program (such as relaxation or mindfulness techniques)
  • You are able and willing to attend sessions remotely (for example, online or by phone)

Who may not be able to join:

  • Your headaches are known or suspected to be caused by a physical condition such as cancer, sinus infection, head injury, or a brain or blood vessel disease
  • You have been diagnosed with another ongoing pain condition, such as fibromyalgia or chronic neck pain, that could make it harder to assess the results
  • You have been diagnosed with a cognitive impairment or dementia
  • You have an active, serious addiction (for example, to cocaine or heroin) that would make it difficult to take part in the study
  • You have a major psychiatric condition such as schizophrenia (note: anxiety and mild to moderate depression do NOT prevent you from joining)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Michael Donnino, MD, Beth Israel Deaconess Medical Center

Phone: 617-754-2882

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
15 November 2024
Est. completion
1 November 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

MIDAS; HIT-6

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov